A Trial of Metformin in Individuals With Fragile X Syndrome

A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome

Sponsors

Lead Sponsor: University of California, Davis

Source University of California, Davis
Brief Summary

This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.

Detailed Description

This is a single-center study at the UC Davis MIND Institute for fragile X syndrome (FXS) patients aged 6 to 25 years inclusive. It is a randomized, double-blind, placebo-controlled trial of metformin (also known as Glumetza, Glucophage, Fortamet), a type 2 diabetes medication that can also improve obesity and excessive appetite.

Metformin has emerged as a candidate drug for the targeted treatment of FXS based on animal studies showing rescue of multiple phenotypes in the FXS model. Metformin may contribute to normalizing signaling pathways in FXS in the central nervous system, which may include activities of mTOR and PI3K, both of which have shown to be pathogenically overactive in FXS. In addition, metformin inhibits phosphodiesterase, which would lead to correction of cAMP levels, and MMP9 production, which is also elevated in FXS. Looking at the potential signaling pathways, metformin appears to be a good candidate for targeting several of the intracellular functions in neurons disrupted in FXS and, therefore, has potential to rescue several types of symptoms in individuals with FXS. The researchers have utilized metformin in the clinical treatment of over 20 individuals with FXS between the ages of 4 and 58 years and have found the medication to be well tolerated and to provide benefits not only in lowering weight gain and normalizing appetite but also in language and behavior. In this controlled trial, the researchers hope to further assess metformin's safety and benefits in the areas of language and cognition, eating and weight loss, and overall behavior.

Each participant will be involved in this trial for a period of 4 months. This will include 3 visits to the UC Davis MIND Institute and 5 phone calls. At each visit, the researchers will assess behavioral, cognitive, and language development. The researchers will also assess the side effects of the study medication throughout the trial.

Study record updated 9/26/2018 to reflect the following IRB-approved protocol modifications: Erroneous references to "digital" books for primary outcome measure were removed, as this measure is administered using print (non-digital) materials. Eligibility criteria were updated to include subjects with IQ of up to and including 79 on the Leiter-III at screening. The Hyperphagia Questionnaire (HQ-CT) was replaced by the Anxiety Depression and Mood Screen (ADAMS) as a secondary outcome measure.

Overall Status Recruiting
Start Date April 30, 2018
Completion Date May 2021
Primary Completion Date May 2021
Phase Phase 2/Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Change from baseline in the Expressive Language Sampling (ELS) mean Number of Different Words (NDW) score Baseline, End of Treatment/Week 16
Secondary Outcome
Measure Time Frame
Change from baseline in the FXS-normed Aberrant Behavior Checklist - Community Edition (ABC-C) Baseline, Week 8, End of Treatment/Week 16
Improvement of symptoms in FXS using the Clinical Impression - Improvement (CGI-I) scale Baseline, Week 8, End of Treatment/Week 16
Change from baseline in the Visual Analog Scale (VAS) Baseline, Week 8, End of Treatment/Week 16
Change from baseline in the Vineland Adaptive Behavior Scales-Third Edition (VABS-III) Adaptive Behavior Composite Score Baseline, End of Treatment/Week 16
Change from baseline in the Anxiety Depression and Mood Screen (ADAMS) overall score Baseline, Week 8, End of Treatment/Week 16
Change from baseline in the Child Sleep Habits Questionnaire (CSHQ) overall score Baseline, Week 8, End of Treatment/Week 16
Change from baseline in the Swanson, Nolan and Pelham Questionnaire (SNAP-IV) overall score Baseline, Week 8, End of Treatment/Week 16
Change from baseline in the Pediatric Quality of Life Questionnaire (PedsQL) Parent Proxy overall score Baseline, Week 8, End of Treatment/Week 16
Enrollment 60
Condition
Intervention

Intervention Type: Drug

Intervention Name: Placebo Medication

Description: Placebo liquid or capsules given in parallel to active medication.

Arm Group Label: Placebo Medication

Other Name: Placebo

Intervention Type: Drug

Intervention Name: Metformin

Description: Active medication.

Arm Group Label: Active Metformin Medication

Eligibility

Criteria:

Inclusion Criteria:

- Molecular genetic confirmation of the full FMR1 mutation or mosaicism.

- Males and non-pregnant, non-lactating females age 6 to 25 years, inclusive.

- Ability of subject and/or caregiver to understand, read, write, and speak English fluently to complete study-related materials.

- IQ ≤ 79 as measured by the Leiter-III at screening.

- Participant is able to speak at least occasional 3-word phrases.

- Participant and parent/caregiver are willing to participate in the protocol and able to attend the clinic regularly and reliably.

- Stable concomitant medication dose and dosing regimen for at least 4 weeks prior to the screening/baseline visit, and the intention to maintain a stable regimen of allowed concomitant medications for the full duration of the study.

- Stable behavioral/educational treatments for at least 4 weeks prior to the screening/baseline visit.

- Sexually active women of childbearing potential must be using a medically acceptable method of birth control for the duration of the study and have a negative urine pregnancy test collected at the initial screening/baseline visit.

- For participants who are not their own legal guardian, the parent/legal authorized representative is able to understand and sign an informed consent to participate in the study.

Exclusion Criteria:

- Non-cooperation or inability to follow through with the study protocol.

- Life-threatening medical problem or other major systemic illness that compromises health or safety and/or would interfere with the study.

- History of intolerable adverse events with metformin.

- Current or recent metformin treatment (within the past year).

- Body mass index (BMI) less than 2 standard deviations for age.

- Serum creatinine > 1.4 mg/dl (female) or > 1.5 mg/dl (male) at screening.

- History of metabolic acidosis or a condition with lactic acidosis.

- Severe B12 deficiency.

- Pregnancy at screening or unwillingness to use acceptable method of birth control, if applicable.

Gender: All

Minimum Age: 6 Years

Maximum Age: 25 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Randi J Hagerman, MD Principal Investigator University of California, Davis
Overall Contact

Last Name: Jasdeep K Shergill, MBS

Phone: 916-703-0471

Email: [email protected]

Location
Facility: Status: Contact: Investigator: UC Davis MIND Institute Jasdeep K Shergill, MBS 916-703-0471 [email protected] Randi J Hagerman, MD Principal Investigator
Location Countries

United States

Verification Date

July 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Placebo Medication

Type: Placebo Comparator

Description: The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.

Label: Active Metformin Medication

Type: Active Comparator

Description: The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.

Acronym Met
Patient Data Undecided
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov